© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
June 26, 2025
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity
June 26, 2025
Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.
ctDNA Blood Test Detected 79% of Colorectal Cancers in Screening Study: Daily Dose
June 26, 2025
Your daily dose of the clinical news you may have missed.
Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis
June 25, 2025
In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.
ACIP Agenda for First Meeting Since Committee Was Replaced by RKF Jr Raises Questions for What's On It and What's Not
June 25, 2025
The now 7-member ACIP will discuss dated issues including thimerosal in flu vaccine and MMR-related febrile seizures but not vaccines against cervical cancer and pneumonia.
Jiade Yu, MD, on the Power of Multidisciplinary Collaboration in Atopic Dermatitis
June 25, 2025
RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.
FDA OKs New Single Pill Combination for HTN Treatment: Daily Dose
June 25, 2025
Your daily dose of the clinical news you may have missed.
A Visible Disease with Invisible Pain: Mona Shahriari Discusses Suicide Risk in Atopic Dermatitis
June 25, 2025
Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
Jiade Yu, MD, on the Future of Chronic Hand Eczema Treatment
June 24, 2025
At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase
June 24, 2025
ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.